BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Bioventus statistics
Financials through Jun 27, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Bioventus | Industry median |
|---|---|---|
| Market Cap | $1.13B | $230.55M |
| Enterprise Value | $1.40B | $202.97M |
| PE Ratio | 17.52 | 31.60 |
| PS Ratio | 1.95 | 3.10 |
| PB Ratio | 4.97 | 3.04 |
| P/FCF Ratio | 12.03 | 27.30 |
| P/OCF Ratio | 11.71 | 22.47 |
Enterprise value
| Measure | Bioventus | Industry median |
|---|---|---|
| EV / Sales | 2.41 | 2.91 |
| EV / EBITDA | 16.77 | 19.74 |
| EV / EBIT | 24.06 | 24.80 |
| EV / FCF | 14.88 | 27.89 |
Income (trailing twelve months)
| Measure | Bioventus | Industry median |
|---|---|---|
| Revenue | $581.85M | $102.39M |
| Gross Profit | $399.45M | $60.36M |
| Operating Income | $58.28M | -$4.31M |
| Pretax Income | $38.64M | -$2.37M |
| Net Income | $54.46M | -$6.57M |
| EBITDA | $83.62M | -$1.98M |
| EPS (Diluted) | $0.77 | -$0.08 |
Margins
| Measure | Bioventus | Industry median |
|---|---|---|
| Gross Margin | 68.7% | 55.2% |
| Operating Margin | 10.0% | -6.04% |
| Pretax Margin | 6.64% | -4.11% |
| Profit Margin | 9.36% | -10.5% |
| EBITDA Margin | 14.4% | -2.67% |
| FCF Margin | 16.2% | 0.02% |
Returns
| Measure | Bioventus | Industry median |
|---|---|---|
| Return on Equity (ROE) | 28.0% | -18.2% |
| Return on Assets (ROA) | 7.89% | -13.3% |
| Return on Invested Capital (ROIC) | 12.7% | -3.69% |
| Return on Capital Employed (ROCE) | 11.2% | -9.07% |
Growth
| Measure | Bioventus | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.14% | 8.85% |
| FCF Growth (YoY) | 176.5% | 9.68% |
| Revenue Growth (3Y CAGR) | 3.52% | 7.08% |
| Revenue Growth (5Y CAGR) | 12.1% | 11.8% |
Balance sheet
| Measure | Bioventus | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $29.46M | $36.66M |
| Total Debt | $248.45M | $97.65M |
| Net Cash (Debt) | -$219.00M | $3.92M |
| Net Cash Per Share | -$2.60 | $0.28 |
| Equity (Book Value) | $228.31M | $55.33M |
| Book Value Per Share | $2.71 | $2.87 |
| Tangible Book Value | -$130.20M | $10.79M |
| Working Capital | $105.08M | $56.72M |
Financial position
| Measure | Bioventus | Industry median |
|---|---|---|
| Current Ratio | 1.69 | 2.48 |
| Quick Ratio | 1.10 | 1.53 |
| Debt / Equity | 1.09 | 0.41 |
| Debt / EBITDA | 2.97 | 2.40 |
| Debt / FCF | 2.64 | 3.49 |
| Net Debt / EBITDA | 2.62 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Bioventus | Industry median |
|---|---|---|
| Operating Cash Flow | $96.87M | -$566.22K |
| Capital Expenditures | -$2.59M | -$3.69M |
| Free Cash Flow | $94.29M | -$696.00K |
| FCF Per Share | $1.12 | -$0.02 |
Efficiency
| Measure | Bioventus | Industry median |
|---|---|---|
| Asset Turnover | 0.84 | 0.58 |
| Inventory Turnover | 2.07 | 2.21 |
| Revenue Per Employee | $625.64K | $322.92K |
| Profits Per Employee | $58.56K | -$51.88K |
| Employee Count | 930 | 185 |
Dividends and yields
| Measure | Bioventus | Industry median |
|---|---|---|
| Earnings Yield | 4.80% | -6.88% |
| FCF Yield | 8.31% | -0.45% |
| Buyback Yield | -0.14% | 0.78% |
| Shareholder Yield | -0.14% | 0.80% |
Shares
| Measure | Bioventus | Industry median |
|---|---|---|
| Shares Outstanding | 84,091,900 | 44,302,700 |
| Shares Change (YoY) | 5.16% | 3.36% |
| Float | 59,712,900 | 37,462,700 |
| Shares Held by Insiders | 29.0% | 10.5% |
| Shares Held by Institutions | 71.2% | 63.5% |
Taxes
| Measure | Bioventus | Industry median |
|---|---|---|
| Income Tax | -$22.84M | $1.52M |
| Effective Tax Rate | -59.1% | 18.5% |
Scores
| Measure | Bioventus | Industry median |
|---|---|---|
| Graham Number | $6.86 | $35.97 |
| Graham Upside | -49.2% | -57.0% |
| Altman Z-Score | 2.44 | 1.95 |
| Piotroski F-Score | 8 | 5 |
| Beneish M-Score | -2.77 | -2.64 |
Calculated by StockData from Bioventus's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.